Member Registration

Members of LabOps Unite: please register here.
Members of BioCT: please register here.
Members of MassBio: please register on this page. Want your organization to gain access to member rates?  Email courses@massbioed.org for more information.

Rates & Funding

Please view the discount options for courses before registering here.

Member Rate: $925
Non-Member Rate: $1,060

Deadline to apply to the WTFP Express Program: March 13, 2026.
Course ID: C-3007

Single Company Offerings

Interested in offering this training exclusively to your team?
Email courses@massbioed.org to learn more.

Description

Finance of Biotech offers a practical introduction to the financial principles that underpin biotech company formation, growth, and long-term success. Participants explore how biotechnology companies are funded across different stages of development and gain insight into the financial decision-making that shapes strategy from early startup through later-stage growth.

The course examines key concepts such as the primary risks of biotech investing, major stages of startup financing, dilutive and non-dilutive funding, company valuation, and common types of investment securities. Led by experienced biotech executives, the course also incorporates real-world perspectives from across the investment ecosystem to help participants understand the differences between private and public markets and how investors evaluate opportunity and risk within life sciences.

Who should attend? This course is ideal for professionals who want to better understand the financial drivers of the biotechnology industry, including scientists, business professionals, project managers, and emerging leaders. It is especially valuable for individuals who interact with investors, support fundraising efforts, contribute to strategic decision-making, or are interested in how financial considerations influence product development and company growth.

For participants looking to apply financial concepts in broader business and operational contexts, this course pairs well with Biotech Commercialization, which explores bringing products to market, as well as Drug Development Pathways, which provides a deeper understanding of development stages and associated risk. Biotechnology Project Management is also a strong complement for those interested in how financial decisions intersect with project execution and resource planning.

Schedule

Monday, April 6, 2026 | 9:00–11:30 AM EST
Monday, April 13, 2026 | 9:00–11:30 AM EST
Monday, April 27, 2026 | 9:00–11:30 AM EST

Meet the Instructors

John Tagliamonte
SVP, Business Development, Tract Bio
John Tagliamonte has more than 30 years of experience in executive leadership with responsibility for business development, finance, commercial operations, strategic planning, and legal functions across public and private life sciences companies. As MassBio’s first Entrepreneur-in-Residence, he helped shape forward-looking program content while mentoring the next generation of biotech entrepreneurs.

Atul Deshpande, Ph.D., MBA
CEO, IMMEDIATE Therapeutics
Atul Deshpande is the Chief Executive Officer of IMMEDIATE Therapeutics, a clinical-stage biotech company dedicated to developing safe and effective therapeutic solutions to reduce heart muscle damage and prevent cardiac arrest in Acute Coronary Syndromes. Previously, he served as Chief Strategy Officer at Peptilogics and led Asia Pacific R&D strategy efforts for Sanofi in China.